Gilead Sciences (GILD) Stock

Gilead (GILD) has been getting a lot of interest from users on Zacks.com recently. As a result, it's important to understand the factors that could affect the stock's future.

FOSTER CITY, Calif.--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD) has announced that The New England Journal of Medicine (NEJM) has published the complete results of its important Phase 3 PURPOSE 2 trial. This trial assessed the effectiveness of lenacapavir, administered twice a year, for preventing HIV in a wide variety of cisgender men and gender-diverse individuals. The findings showed that this treatment was very effective in reducing the risk of HIV.

BETHESDA, Md.--(BUSINESS WIRE)--The Children's Inn at the National Institutes of Health (NIH) has received a $1 million grant from Gilead Sciences Inc. to help with its renovation and expansion. This funding will be used to create a welcome center in the new section of The Inn of Tomorrow, which is part of a larger project costing over $50 million that recently had its groundbreaking ceremony. The Gilead Sciences Welcome Center will serve as the first point of contact for young patients from around the world.

Gilead Sciences, Inc. (NASDAQ:GILD) will be participating in the Jefferies London Healthcare Conference on November 20, 2024, at 4:30 AM ET. The company will be represented by Dan O'Day, the Chairman and CEO, and Andy Dickinson, the CFO. Michael Yee, a senior biotechnology analyst at Jefferies, will be hosting the management team from Gilead on stage.

On Friday, Gilead Sciences, Inc. (GILD) shared results from a two-and-a-half-year interim analysis of the ongoing Phase 3 ASSURE study. This study is looking at the long-term effectiveness and safety of Livdelzi.

FOSTER CITY, Calif.--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD) has shared results from a two-and-a-half-year interim analysis of the ongoing Phase 3 ASSURE study. The findings revealed that 81% of participants with primary biliary cholangitis (PBC) who received Livdelzi® (seladelpar) showed a significant biochemical response, indicating important progress in managing the disease. Furthermore, 41% of the participants were able to return to normal levels.

Investors frequently depend on analyst recommendations when choosing to buy, sell, or keep a stock. Changes in ratings from these analysts, who work for brokerage firms, can impact a stock's price, but how significant are they really?

Gilead (GILD) has recently caught the attention of Zacks.com users. Therefore, it's important to look into what the future holds for this stock.

Gilead Sciences, a major biopharmaceutical company, has announced that it will close its office located in the Eastlake area of Seattle, as confirmed to GeekWire on Wednesday.